MM 310

Drug Profile

MM 310

Alternative Names: MM-310

Latest Information Update: 31 Mar 2017

Price : $50

At a glance

  • Originator University of California at Los Angeles
  • Developer Merrimack Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Eph family receptor modulators; EphA2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 23 Mar 2017 Phase-I clinical trials in Solid tumours (Second-line therapy or greater) in USA (IV) (NCT03076372)
  • 09 Mar 2017 MM-310 licensed to Merrimack Pharmaceuticals worldwide (Merrimack Pharmaceuticals Annual Report, March 2017)
  • 09 Mar 2017 Merrimack Pharmaceuticals has patent protection for MM-310 in USA, Europe and other countries (Merrimack Pharmaceuticals Annual Report, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top